1. < Post-COVID Recovery & COVID-19
Profile picture for sanDGuy

Interesting study coverage from Wired magazine, of all places

Posted by sanDGuy @sandguy, Nov 17 6:41pm

Of course, Wired tends to be concerned with technology primarily and I think I've subscribed since their earliest beginnings,
but here's their coverage of this new study being conducted at Scripp Research looking for subjects to try out a GLP-1 drug as a possible treatment due to its anti-inflammatory properties:
https://www.wired.com/story/weight-loss-drug-zepbound-is-being-tested-as-a-treatment-for-long-covid/
If many people find they're blocked by a paywall, please comment and I'll just pirate post the text below.

Interested in more discussions like this? Go to the Post-COVID Recovery & COVID-19 Support Group.

Profile picture for pattig09
pattig09 | @pattig09 | Nov 22 4:30pm
In reply to @sandguy "@pattig09 Thanks for that! Plus, there's a pretty cute cartoon at the top of that page...." + (show)
Profile picture for sanDGuy @sandguy

@pattig09
Thanks for that! Plus, there's a pretty cute cartoon at the top of that page.
I've gone ahead and have been taking the Metformim--1000mg. daily--for about a week now, and will report back if I feel any effects (none so far).

Jump to this post

@sandguy University of Minnesota did 2 studies for Metformim prescription use. 1. focus was on diabetics and the 'prevention' of those patients from getting long covid; and, 2. Prevention for diabetic patients from getting ME/CFS following COVID-19 infections. https://recovercovid.org/r3-seminar-series/understanding-metformin-use-and-long-covid-and-mecfs-following-covid-19-infection

REPLY
View MoreView Less
Please sign in or register to post a reply.